Is Daprodustat currently available in China and the latest status of China’s marketing approval

Daprodustat is an oral HIF-PH inhibitor primarily used to treat anemia associated with chronic kidney disease. This drug improves anemia symptoms by inhibiting the hypoxia-inducible factor prolyl hydroxylase and promoting the production of endogenous erythropoietin (EPO). Although the original drug has been approved and widely used in overseas markets, in the domestic market, the original drug of daprostat has not yet been officially launched, so patients are currently unable to purchase it directly through regular hospital pharmacies.

In China, daprostat has not yet been included in the national medical insurance directory, which means that even if it is launched in the future, patients' out-of-pocket burden may still be high. At present, there is no official price information in the country, and there are no hospitals or pharmacies for direct purchase. Therefore, for patients who urgently need daplostat, domestic access is very limited, and treatment mainly relies on traditional erythropoietin injections or other anemia management options.

In overseas markets, the original drug of dapocestat is already available. The common specifications are 1mg30 tablets and 2mg30 tablets. The price per box is approximately 100 to 500 Prices may fluctuate between U.S. dollars due to exchange rates and market factors. At the same time, the first generic version of daprostat has appeared overseas. For example, Lucius Pharmaceuticals of Laos produces 1mg*100 tablets, and each box sells for about more than 400 yuan. Generic drugs have basically the same ingredients as original drugs, providing certain options for patients who cannot obtain them through original drugs.

Overall, dapostat is still not on the market in China, and neither the original drug nor medical insurance support is in place, so direct use by domestic patients is restricted. A certain supply system has been formed for overseas original drugs and generic drugs. If patients need it, they can learn about the cross-border acquisition plan through formal channels. At the same time, clinical application should be carried out strictly under the guidance of doctors to ensure safety and efficacy.

Keyword tag:

Daprostat, domestic purchase, listing in China, approval status, medical insurance, original drugs, generic drugs, overseas markets, drug purchase channels

Reference materials:https://go.drugbank.com/drugs/DB13973